S095029

Phase 2Small molecule

SServier Bio-Innovation LLC

S095029 is one of 100 small molecule programs targeting Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Active, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Non-Small Cell Lung Cancer (NSCLC)Preclinical

Active, not recruiting

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Adrucil

EElorac, Inc.

Phase 3

86 2

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

58 3

XL092

Roche

Phase 3

1 4

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 5

Iron Isomaltoside

TThomas Jefferson University

Phase 3

3 6

Mfolfoxiri

DDominik Paul Modest

Phase 3

3 7

Tucidinostat

CChipscreen Biosciences, Ltd.

Phase 3

1 8

Leucovorin and 5-FU

AAkeso

Phase 3

1 9

Trodelvy

Gilead

Preclinical

1 10

S095029

SServier Bio-Innovation LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT06162572

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Active, not recruiting·SServier Bio-Innovation LLC·Phase 1/2·NCT06116136·48 enrolled

Colorectal Cancer1 trial

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Active, not recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1·NCT05162755·41 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression

Active, not recruiting·SServier Bio-Innovation LLC·Preclinical·NCT06162572·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for S095029. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S095029 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S095029. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Servier Bio-Innovation LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SServier Bio-Innovation LLC

S095029

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Gastric Cancer1 trial

Colorectal Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News